Structure Encountered

Earendil Labs

AI-driven biologics company developing bispecific and multispecific antibodies for autoimmune disease and cancer.

Earendil Labs dosed first cohort with HXN-1011, an AI-designed biparatopic anti-TSLP antibody, two months after its $787M raise.

SIGNAL·Phase 1 first cohort dosed·Two months after $787M·SCORE 82·19 MAY 2026 · 12:47 UTC

● CAPTURE — IMAGE INCOMINGFRAME 01 / 01

Structure Earendil Labs, captured by Voyager

STRUCT. / EARENDIL LABS

/ Wilmington, Delaware

CAPT. / 19.05.26 12:47:05Z

SIGNAL / 82 / 100

Image relayed by The Biotech Voyager during pass over structure Earendil Labs. Resolution as transmitted.

001Vital Statistics

DATA LOCKED

Designation

Earendil Labs

Coordinates

Wilmington, Delaware

Stage

Phase 1

Type

Therapeutics

Modalities

antibody · bispecific · biparatopic · ADC · AI/ML

Therapeutic area

Immunology · Respiratory · Dermatology · Oncology

002Signature Detected

EVENT DETECTED

Event type

Phase 1 first cohort dosed

Magnitude

Two months after $787M

Lead

Earendil Labs

Participating

Sanofi (partner on separate programs), WuXi Biologics, WuXi XDC

003Architecture

PLATFORM PROFILE

Target class

Thymic stromal lymphopoietin (TSLP), an alarmin cytokine driving Th2 inflammation in asthma, atopic dermatitis, and other type-2 disease.

Differentiator

Tezepelumab binds one site on TSLP and blocks the heterodimer that way. HXN-1011 grabs two epitopes at once and blocks both receptor subunits, TSLPR and IL-7Rα. AI-designed, sub-q at high concentration.

Lead asset

HXN-1011, biparatopic anti-TSLP antibody, Phase 1

Pipeline depth

Disclosed clinical: HXN-1011 (TSLP, Ph1), HXN-1001 (anti-TL1A, Ph2a UC). Earlier Sanofi-licensed: HXN-1002, HXN-1003.

004Voyager Assessment

MACHINE-GENERATED

Two months ago Earendil pulled $787M, the largest AI-bio round of 2026. Now they have HXN-1011 in humans, an AI-designed biparatopic that hits TSLP at two epitopes and blocks both receptor subunits at once. Tezepelumab does one. The indication wasn't disclosed, which is interesting on its own. Earendil already has HXN-1001 in a Phase 2a in ulcerative colitis and two more bispecifics licensed to Sanofi. The thesis is that AI design buys you better mechanics on validated targets. The clinic gets to decide.

005Adjacent Structures

FRONTIER MAP

Windward Bio· anti-TSLP, $365M raisedAstraZeneca· tezepelumab incumbentAmgen· tezepelumab co-developerUpstream Bio· TSLP for severe asthmaSanofi· $2.5B Earendil partnerHarbour BioMed· AI bispecific platformRecursion· AI-driven biologics peer

— End of transmission —This signal was received and processed by The Biotech Voyager and HOUSTON. Transmissions are auto-generated from public sources and platform telemetry. They are not edited for prose. For human analysis and connection to other signals, watch the Tuesday or Thursday mission broadcast aboard the [SHIP]. Field notes — long-form synthesis from the crew — are archived separately.